Calamos Advisors LLC Has $930,000 Holdings in Natera, Inc. $NTRA

Calamos Advisors LLC decreased its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 77.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,777 shares of the medical research company’s stock after selling 20,345 shares during the period. Calamos Advisors LLC’s holdings in Natera were worth $930,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. SWS Partners lifted its stake in Natera by 11.8% in the 3rd quarter. SWS Partners now owns 47,037 shares of the medical research company’s stock valued at $7,572,000 after acquiring an additional 4,980 shares in the last quarter. Vontobel Holding Ltd. raised its holdings in shares of Natera by 192.5% in the third quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company’s stock valued at $1,373,000 after purchasing an additional 5,614 shares during the last quarter. Baird Financial Group Inc. raised its holdings in shares of Natera by 277.8% in the second quarter. Baird Financial Group Inc. now owns 26,624 shares of the medical research company’s stock valued at $4,498,000 after purchasing an additional 19,576 shares during the last quarter. Orion Porfolio Solutions LLC lifted its position in shares of Natera by 68.8% in the second quarter. Orion Porfolio Solutions LLC now owns 12,140 shares of the medical research company’s stock worth $2,051,000 after purchasing an additional 4,946 shares in the last quarter. Finally, Park Avenue Securities LLC acquired a new position in Natera during the second quarter worth $1,525,000. 99.90% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Roy D. Baynes sold 7,668 shares of Natera stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $223.08, for a total transaction of $1,710,577.44. Following the completion of the sale, the director owned 18,359 shares of the company’s stock, valued at approximately $4,095,525.72. The trade was a 29.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Roelof Botha sold 75,000 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $236.12, for a total transaction of $17,709,000.00. Following the completion of the transaction, the director owned 1,154,198 shares in the company, valued at approximately $272,529,231.76. This trade represents a 6.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 336,481 shares of company stock valued at $72,008,879. 5.63% of the stock is owned by company insiders.

Natera Stock Down 0.4%

NASDAQ:NTRA opened at $229.09 on Friday. Natera, Inc. has a 12-month low of $125.38 and a 12-month high of $246.90. The firm has a market capitalization of $31.69 billion, a price-to-earnings ratio of -100.04 and a beta of 1.63. The stock’s 50 day moving average price is $221.36 and its two-hundred day moving average price is $183.15.

Natera (NASDAQ:NTRA) last issued its earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business had revenue of $592.18 million for the quarter, compared to the consensus estimate of $514.55 million. During the same quarter in the prior year, the firm posted ($0.26) earnings per share. The business’s revenue was up 34.7% compared to the same quarter last year. Equities research analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Ratings Changes

NTRA has been the topic of several recent research reports. Piper Sandler lifted their price target on shares of Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Canaccord Genuity Group raised their price objective on Natera from $250.00 to $285.00 and gave the company a “buy” rating in a report on Monday, December 22nd. Stephens upped their target price on Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Barclays increased their price target on Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Finally, Evercore ISI boosted their price target on Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Fifteen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $231.18.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.